GWPH Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of GW Pharmaceuticals plc Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – GWPH

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether GW Pharmaceuticals plc (NASDAQ: GWPH) and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders in connection with the proposed sale of GW Pharmaceuticals to Jazz Pharmaceuticals plc for $200.00 in cash and $20.00 in Jazz ordinary shares for each GW American Depositary Share (ADS).

On behalf of GW Pharmaceuticals shareholders, Halper Sadeh LLP may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.

Halper Sadeh encourages GW Pharmaceuticals shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at [phone] or [e-mail] or [e-mail].

Halper Sadeh LLP represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.